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Abstract
 .Liposomal vectors formulated with cationic lipids cationic liposomes and fusogenic dioleoylphosphatidylethanolamine
 .DOPE have potential for modulating the immune system by delivering gene or antisense oligonucleotide inside immune
cells. The toxicity and the immunoadjuvant activity of cationic liposomes containing nucleic acids toward immune effector
cells has not been investigated in detail. In this report, we have evaluated the toxicity of liposomes formulated with various
cationic lipids towards murine macrophages and T lymphocytes and the human monocyte-like U937 cell line. The effect of
 .these cationic liposomes on the synthesis of two immunomodulators produced by activated macrophages, nitric oxide NO
 .and tumor necrosis factor-a TNF-a , has also been determined. We have found that liposomes formulated from DOPE and
cationic lipids based on diacyltrimethylammonium propane dioleoyl-, dimyristoyl-, dipalmitoyl-, disteroyl-: DOTAP,
.  .DMTAP, DPTAP, DSTAP or dimethyldioctadecylammonium bromide DDAB are highly toxic in vitro toward phagocytic
 .cells macrophages and U937 cells , but not towards non-phagocytic T lymphocytes. The rank order of toxicity was
DOPErDDAB)DOPErDOTAP)DOPErDMTAP)DOPErDPTAP)DOPErDSTAP. The ED ’s for macrophage50
toxicity were -10 nmolrml for DOPErDDAB, 12 nmolrml for DOPErDOTAP, 50 nmolrml for DOPErDMTAP, 400
nmolrml for DOPErDPTAP and )1000 nmolrml for DOPErDSTAP. The incorporation of DNA antisense oligonucleo-
.tide or plasmid vector into the cationic liposomes marginally reduced their toxicity towards macrophages. Although
toxicity was observed with cationic lipids alone, it was clearly enhanced by the presence of DOPE. The replacement of
 .DOPE by dipalmitoylphosphatidylcholine DPPC significantly reduced liposome toxicity towards macrophages, and the
 .presence of dipalmitoylphosphatidylethanolamine-PEG DPPE-PEG : 10 mol% in the liposomes completely abol-2000 2000
ished this toxicity. Cationic liposomes, irrespective of their DNA content, downregulated NO and TNF-a synthesis by
 .  .lipopolysaccharide LPS rinterferon-g IFN-g -activated macrophages. The replacement of DOPE by DPPC, or the
addition of DPPE-PEG , restored NO and TNF-a synthesis by activated macrophages. Since macrophages constitute the2000
major site of liposome localization after parenteral administration and play an important role in the control of the immune
system, cationic liposomes should be used with caution to deliver gene or antisense oligonucleotide to mammalian cells.
Abbreviations: DOPE, dioleoylphosphatidylethanolamine; DPPC, dipalmitoylphosphatidylcholine; DOTAP, dioleoyl-, DMTAP,
dimyristoyl-, DPTAP, dipalmitoyl-, DSTAP, distearoyl-diacyltrimethyammonium propane; DDAB, dimethyldioctadecylammonium bro-
mide; DPPE-PEG , dipalmitoylphosphatidylethanolamine-polyethylene glycol ; NBD-PE, 7-nitro-2-1,3-benzoxadiazol-4-yl-phos-2000 2000
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Cationic lipids show in vitro toxicity toward phagocytic cells and inhibit in vitro and in situ NO and TNF-a production by
activated macrophages. q 1997 Elsevier Science B.V.
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1. Introduction
Liposomes formulated with cationic lipids ca-
.tionic liposomes are usually used to deliver DNA or
w xRNA inside mammalian cells 1 . Most liposomes
used for this purpose are composed of cationic lipids
which can form stable complexes with the anionic
nucleic acids, and dioleoylphosphatidylethanolamine
 .DOPE which can destabilize the endosome com-
partment and cause the release of nucleic acids into
w xthe cytoplasm 2 . Lipofection, or liposomal nucleic
acid transfer, offers a number of advantage over
current methods of transfection such as calcium phos-
phate precipitation, electroporation, direct injection or
retroviral-mediated transfer. Cationic liposomes are
very efficient in gene delivery in vitro, do not disrupt
the cell membrane, are capable of transfecting many
cell types, are metabolizable and have the potential to
w xtarget specific tissues in vivo 3 . Cationic liposomes
may be useful in the treatment of a number of
diseases, including DNA delivery for gene therapy.
An example is the use of DOPErdimethyl-
 .aminoethanecarboyl–cholesterol DC–Chol lipo-
somes that are currently being evaluated for the
delivery of the chloride transporter gene to the lungs
w xof individuals with cystic fibrosis 4 . Cationic lipo-
somes may also be useful for the delivery of anti-
sense oligonucleotides capable of inhibiting tumor
w xcell propagation 5 . Cationic liposomes containing
appropriate nucleic acids antisense DNA or plasmid
.vector have the potential to act as immunomodula-
tors to improve current anti-microbial, anti-viral or
anti-inflammatory therapy. However a lack of toxic-
ity and immunomodulatory studies precludes any
generalization as to their innocuity toward the im-
mune system.
The limited number of toxicity studies on lipo-
somes formulated with cationic lipids have used
w xnon-immune, non-phagocytic cells 6,7 , or non-
w xphagocytic immune cells such as T lymphocytes 8 .
Prior to evaluating the potential of cationic liposomes
as a delivery vehicle for nucleic acid immunotherapy
we felt it prudent to examine the toxicity of different
formulations towards two major immune effector cell
populations, macrophages and T lymphocytes.
Macrophages constitute the major site of liposome
w xlocalization after parenteral administration 9 .
Macrophages, which are known to present antigens,
have the capacity to phagocytosis a large quantity of
antigen or liposomes, while T lymphocytes do not
w xhave this capacity 10 . We have further evaluated the
effect of liposomes containing cationic lipids on the
 .production of nitric oxide NO and tumor necrosis
 .factor-a TNF-a , two important immunomodulator
secreted by activated macrophages. The production of
NO by activated macrophages provides an early
non-specific defence against pathogens prior to the
development of a specific immune response, can
regulate the development of T-helper 1 and T-helper
2 immunity and is implicated in the inflammatory
w xprocess 11 . TNF-a , which is produce predominately
by macrophages, has an anti-viral and an anti-tumoral
activity, enhances T and B lymphocyte responsive-
ness and also plays an important role in inflammatory
w xreactions 12 .
Our results show that liposomes formulated with
DOPE and cationic lipids are highly toxic for phago-
cytic macrophages and monocyte-like U937 cells, but
not for non-phagocytic T lymphocytes. Toxicity and
downregulation of NO and TNF-a was related to the
presence of cationic lipid and was enhanced by DOPE.
The incorporation of DNA, as either an antisense
oligonucleotide or as the plasmid vector pBR322,
marginally reduced cationic liposomes toxicity to-
ward macrophages, but did not reduced the ability of
cationic lipids to non-specifically downregulate NO
and TNF-a synthesis by activated macrophages.
2. Materials and methods
2.1. Liposomes preparation
Glassware was treated at 1808C for 4 h to inacti-
vate endotoxin. Sterile pyrogen-free NaCl 0.85%
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.wrv was used to prepare all solutions and all manip-
ulations were carried out in a class 100 horizontal
laminar flow cabinet. Cationic lipids dioleoyl-
w x w xDOTAP , dimyristoyl- DMTAP , dipalmitoyl-
w x w xDPTAP , distearoyl- DSTAP diacyl trimethyl-
ammonium propane; Avanti Polar Lipids, Alabaster,
AL or dimethyldioctadecylammonium bromide
w x .DDAB ; Sigma, St.-Louis, MO were dissolved in
 .chloroform 10 mgrml , mixed at a molar ratio of
1:1 with DOPE or with dipalmitoylphosphatidyl-
 .  . choline DPPC 20 mmol of each Avanti Polar
.Lipids and evaporated to dryness at 608C in a
round-bottomed flask using a rotary evaporator. Am-
phiphilic dipalmitoylphosphatidylethanolamine-
 .PEG DPPE-PEG , 10 mol% final concentra-2000 2000
 .tion Shearwater Polymers, Huntsville, AL or fluo-
rescent 7-nitro-2-1,3-benzoxadiazol-4-yl-phospha-
 .tidylethanolamine NBD-PE , 5 m grm mol
 .  .lipidrphospholipid Avanti Polar Lipids was dis-
solved in chloroform and mixed with cationic
lipidrphospholipid prior to rotary evaporation. Multi-
 .lamellar liposomes non-sonicated were prepared by
adding the required volume of 0.85% wrv NaCl 1
.mlr10 mmol cationic liposomes followed by agita-
 .tion. Unilamellar liposomes -0.12 mm were ob-
tained by sonication.
2.2. Incorporation of DNA into cationic liposomes
w XThe antisense oligonucleotide 5 GAC TTT GAA
X xGAG GAG AAA 3 was synthesized using an auto-
mated DNA synthesizer Beckman Oligomer 1000,
.Columbia, MD by the Department of Biochemistry,
Universite de Montreal. The antisense DNA was´ ´
purified by several cycles of ethanol precipitation,
and was resuspended in DNAse-free water before
 .use. Purified pBR322 plasmid 4363 bp was kindly
provided by Dr. Philippe Raymond Institut
.Armand-Frappier, Laval, Quebec, Canada . Antisense´
 .oligonucleotide 2.0, 10.0 and 25.0 mg or plasmid
 .0.1, 0.5 and 2.5 mg were mixed with 0.01, 0.1 or
1.0 mmolrml of uni lamellar cationic liposomes
 .composed of DOPErDOTAP 1:1 mol ratio and
incubated for 30 min at room temperature before use.
2.3. Liposomes characterization
The size of reconstituted liposomes was deter-
mined by photo correlation spectroscopy in a Coulter
4N Plus submicron particle analyser Coulter, Miami,
.  .FL . Liposomal charge, measured as the zeta z
potential, was determined in 0.85% wrv NaCl
buffered to pH 7.4 with 10 mM sodium phosphate
.buffer by Doppler electrophoretic light scattering
using a Coulter DELSA 440 SX.
2.4. Cells
Macrophages were obtained by i.p. injection of
female CD1 mice Charles River, St-Constant,
.Canada with 1.5 ml sterile Brewer’s thioglycollate
 .broth Difco, Detroit, USA . The peritoneal exudate
 .)85% macrophages was harvested 4 days later,
washed by centrifugation in Hank’s balanced salt
 .solution HBSS and seeded in 96-well flat-bottom
micro plates at 1.0 =105 macrophagesrwell in
RPMI-1640 containing 10% heat-inactivated fetal calf
 .serum FCS , 50 mgrml gentamycin sulphate and 20
mM of HEPES all from Gibco Life Science,
.Burlington, Canada . T cells were isolated from fe-
male CD1 spleen cells. Spleens were aseptically re-
moved and single cell suspension were prepared by
gentle teasing through sterile stainless steel screens.
 .Cell suspensions 10 ml were layered on Lym-
pholyte-M cell separation media 5 ml; CedarLane,
.Hornby, Ontario, Canada and centrifuged at 2200
rpm for 30 min to remove red blood cells and dead
cells. The cells were washed by centrifugation 15 ml
.medium, 1500 rpm for 10 min . T cells were purified
by Thy1.2 positive selection using magnetic micro
beads MiniMacs cell sorter, Miltenyi Biotec, Bergish
. 5Gladbach, Germany and seeded at 1.0=10 T
cellsrwell in 200 ml RPMI 1640r10% FCS. Acti-
vated T lymphocytes were obtained by adding 105
spleen feeder cellsrwell and 1% of phytohaemagglu-
 .  .tinin-A PHA Gibco Life Science for 24 h as
w xpreviously described 13 . Human monocyte-like
U937 cells were obtained from the American Type
 .Culture Collection Rockville, MD and cultured in
RPMI 1640r10% FCS at 378C, 5% CO .2
2.5. Toxicity assay
Liposome toxicity towards immune effector cells
w xwas determined as previously described 14 . Briefly,
5 1.0=10 cellrwell macrophages, T cells or U937
.cell in 100 ml medium were incubated with the
indicated liposome formulation at different concentra-
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tions at 378C, 5% CO for 24 h. Lactate dehydroge-2
 .nase LDH activity in the medium was used as an
indicator of cell death, and was determined by means
 .of a commercial kit Sigma Chemical . Total LDH
activity was determined by incubating the cells with
1.0% vrv Triton X-100 in water to induce lysis,
followed by vigorous agitation.
2.6. NO and TNF-a determination
 5 .Macrophages 1=10 cellsrwell in 100 ml
medium were incubated with the indicated liposomes
for 3 h at 378C, 5% CO and washed 3 times with2
200 m l warm RPMI-1640r10%FCS. The
macrophages were then incubated with E. coli 011:B4
 .  . lipopolysaccharide LPS rinterferon-g IFN-g 1.0
. mgrml and 500 Urml respectively LPS from
.Sigma, IFN-g from Gibco Life Science for 48 h in a
final volume of 200 ml. NOy, one of the end prod-2
ucts of NO synthesis, was measured after 48 h incu-
bation by mixing 50 ml cell supernatant with 50 ml
of Griess Reagent 1% sulfanilamide in 2.5% H PO3 4
mixed with an equal volume of 0.1% N- 1-
. .naphthyl ethylenediamine HCl in H O and deter-2
mining the absorbance at 550 nm against NaNO2
standards. TNF-a synthesis was measured by means
of a commercial ELISA kit BioSource, Camarillo,
.CA using 50 ml supernatant. LDH was determined
 .as described earlier Section 2.5 at 3, 24 and 48 h
using 2 ml supernatant. For in situ macrophage treat-
ment, cationic liposomes were injected i.p. 60
.mgrkg in a volume of 500 ml on day 3 following
the injection of thioglycollate broth. The macrophages
were harvested on day 4 and NO and TNF-a synthe-
sis measured after LPSrIFN-g as described above.
2.7. Liposomes endocytosis assays
Macrophages and monocyte-like U937 cells 5=
5 .10 cellsrwell were incubated in 6-well flat-bottom
 .micro plate 1.0 ml with the indicated fluorescent
 .NB-PE liposomes 10 mmolrml for 4 h at 378C, 5%
CO . At the end of the incubation the cells were2
 .washed twice with ice-cold HBSS 3.0 ml and then
lysed in HBSS containing 0.5% Triton X-100 1.0
.ml . Fluorescence was measured using excitation and
emission wavelengths of 460 nm and 534 nm respec-
tively. Experiments were also carried out in parallel
at 48C and endocytosis was calculated from the re-
w xsults obtained at 378C minus those at 48C 15 . Re-
sults were expressed as nmol of lipidr5=105 cellsr4
h.
3. Results
3.1. Liposomes diameter and z potential
Two populations of cationic liposomes with differ-
ent sizes were used in this study: unilamellar lipo-
somes with a diameter -0.12 mm and multilamellar
liposomes with a diameter )1.00 mm. There was no
evidence of liposomes aggregation on storage at 48C
over a period of 24 h. The liposomal charge, mea-
sured as the z potential, was also determined Table
.1 . The rank order of liposomal z potential was
D O P E r D D A B s D O P E r D O T A P s
DOPErDMTAP)DOPErDPTAP)DOPErDSTAP
 .1:1 mol ratio , and was found to be independent of
liposomes diameter.
Table 1
Liposome characterization
 .  .Liposome formulations z potential Size mm Size mm
 .mV non-sonicated sonicated
DOPErDDAB q40.0"9.0 1.05–3.20 0.10–0.12
DOPErDOTAP q42.0"10.9 1.00–1.33 0.08–0.11
DOPErDMTAP q42.9"12.5 1.75–3.19 0.10–0.12
DOPErDPTAP q22.4"3.0 3.00–5.87 0.09–0.12
DOPErDSTAP q15.0"6.3 5.31–10.00 0.11–0.12
DPPCrDOTAP q42.6"6.2 1.09–1.46 0.08–0.10
DOPErDOTAPqDPPE-PEG q3.2"3.0 1.15–1.46 0.08–0.102000
 .Liposome charge, measured as the z potential, and liposome size were determined in NaCl 0.85% wrv at 258C. z potential is
expressed as the mean"S.D. of 3 independent experiments. Liposome size is expressed as the range of 3 independent experiments.
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3.2. Toxicity of cationic liposomes toward
macrophages and T lymphocytes
Liposomes formulated at a 1:1 mol ratio phos-
.pholipidrcationic lipid were highly toxic toward
macrophages as determined by the release of LDH
 .into the cell supernatant Fig. 1 . The rank order of
toxicity was DOPErDDAB ) DOPErDOTAP )
DOPErDMTAP)DOPErDPTAP)DOPErDSTAP.
Similar results were obtained with monocyte-like
U937 cells, and these results were confirmed by
 .trypan blue exclusion tests data not shown . The
ED ’s for macrophage toxicity were -10 nmolrml50
for DOPErDDAB, 12 nmolrml for DOPErDOTAP,
50 nmolrml for DOPErDMTAP, 400 nmolrml for
DOPErDPTAP and ) 1000 nmolrml for
DOPErDSTAP. Toxicity was not influenced by the
 .diameter of liposomes -0.12 mm vs. )1.00 mm
but was influenced by the presence of 10% FCS
 .during the first 3 h of incubation Fig. 1 . The
absence of FCS during the first 3 h of a 48 h
incubation in complete medium containing 10% FCS
increased the toxicity of cationic liposomes toward
macrophages. However, incubation of macrophages
in the absence of cationic liposomes and FCS during
the first 3 h of incubation did not increase
macrophages death as measured by the LDH release.
As illustrated in Fig. 1 for DOPErDOTAP lipo-
somes, none of the cationic liposomes tested showed
toxicity toward purified T lymphocytes in the pres-
ence or absence of FCS during the first 3 h of
incubation. Furthermore, the liposomes showed no
toxicity towards T cells activated by the mitogenic
 .agent PHA Fig. 1 .
3.3. The incorporation of DNA in cationic liposomes
does not significantly reduce toxicity toward
macrophages
We have evaluated whether the incorporation of
DNA, as either a single stranded antisense oligo-
 .nucleotide 15 mers or as the double stranded plas-
Fig. 1. Cationic liposomes were toxic for macrophages but not
 5 .for T lymphocytes. Macrophages 1=10 rwell were incubated
with the indicated cationic liposomes DOPErDDAB v,
DOPErDOTAP %, DOPErDMTAP ’, DOPErDPTAP B,
.DOPErDSTAP l for 24 h at 378C, 5% CO in RPMI-2
 .1640r10% FCS. Resting e or activated T cells by 1% of PHA
 .I were incubated with DOPErDOTAP liposomes for 24 h. at
378C, 5% CO in RPMI-1640r10% FCS. The diameter of the2
 .  .liposomes used was 0.08–0.12 mm unilamellar a and 1.00–
 .  .  .10.00 mm multilamellar b . In c , macrophages or T cells
were incubated with unilamellar liposomes in 100 ml of RPMI-
1640 without FCS for 3 h at 378C, 5% CO . Then, 100 ml of2
complete medium containing 20% FCS final concentration: 10%
.FCS was added to the corresponding well and incubated for a
further 21 h. Toxicity was determined by the release of LDH
activity into the supernatant after 24 h incubation. Data represent
the mean"S.D. of two replicates of three independent experi-
ments.
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Fig. 2. The incorporation of DNA in cationic liposomes
marginally reduced the toxicity observed towards macrophages.
 . w  .  .  .xIn a plasmid pBR322 0.1 l , 0.5 ’ and 2.5 mg B or in
 . w  .  .b antisense oligonucleotides 2.0 l , 10.0 ’ and 25.0 mg
 .xB were mixed with 0.01, 0.1 and 1.0 mmolrml of unilamellar
 .DOPErDOTAP liposomes 1:1 mol ratio and incubated for 30
min at room temperature. The diameter of plasmid pBR322rca-
tionic liposomes was between 0.3–3.8 mm and was between
0.1–1.0 mm for antisense DNArcationic liposomes. Macrophages
 5 .1=10 rwell were incubated with the indicated cationic lipo-
somes for 24 h at 378C, 5% CO in RPMI-1640r10% FCS.2
Toxicity was determined by the release of LDH activity into the
supernatant after 24 h incubation. Data represent the mean"S.D.
of two replicates of three independent experiments.
 .mid vector pBR322 4363 bp , in cationic liposomes
can reduced the observed toxicity toward
macrophages. The incorporation of different amounts
of DNA by different concentrations of unilamellar
DOPErDOTAP liposomes, some of which represent
the optimal cationic liposomesrDNA ratio that is
w xcurrently used for in vitro transfection 16 , did not
significantly reduce the toxicity observed toward
 .macrophages Fig. 2 . Nevertheless, the incorporation
of antisense or plasmid DNA into cationic liposomes
 .significantly reduced the z potential Table 2 .
3.4. The addition of DPPE-PEG abolished the2000
toxicity toward macrophages
The fact that cationic liposomes are highly toxic
toward macrophages but not toxic toward T lympho-
cytes could be explained by the enhanced relative
phagocytic activity of macrophages compared to T
cells. To test this hypothesis we have incorporated
into DOPErDOTAP liposomes 10 mol% of DPPE-
PEG . The presence of DPPE-PEG in lipo-2000 2000
w xsomes blocks endocytosis but not pinocytosis 15 .
The toxicity of the liposomes toward macrophages
and monocyte-like U937 cells was completely abol-
ished by the incorporation of DPPE-PEG into2000
 .DOPErDOTAP liposomes Fig. 3 . The addition of
DPPE-PEG significantly decreased the z poten-2000
tial of DOPErDOTAP liposomes DOPErDOTAP:
42.0"10.9 mV vs. DOPErDOTAP q10 mol%
.DPPE-PEG : 3.2"3.0 mV .2000
3.5. The replacement of DOPE by DPPC reduced the
toxicity toward macrophages
DOPE is a pH-sensitive phospholipid that can
destabilize the endosomal membrane at acidic pH and
assist liposomes in delivering their contents into the
w xcytoplasm 2 . The association of DOPE with cationic
Table 2
The incorporation of DNA by cationic liposomes influences the z
potential
 .  .DNA z potential mV DOPErDOTAP mmol
0.01 0.1 1.0
pBR322, 0.1 mg q3.2"2.9 q25.6"23.5 q42.2"18.5
pBR322, 0.5 mg q1.9"0.7 q13.3"19.7 q25.0"23.2
pBR322, 2.5 mg q0.7"6.5 q10.6"24.1 q17.1"21.3
antisense, 2.0 mg q2.0"14.1 q21.7"10.0 q41.1"12.3
antisense, 10.0 mg y8.8"12.3 y3.9"15.7 y2.3"13.6
antisense, 25.0 mg y11.2"16.0 y10.4"24.0 y9.0"18.1
 . Plasmid pBR322 0.1, 0.5 and 2.5 mg or antisense DNA 2.0,
.10.0 and 25.0 mg were mixed with 0.01, 0.1 or 1.0 mmolrml of
 .unilamellar DOPErDOTAP liposomes 1:1 mol ratio and incu-
bated for 30 min at room temperature. Liposome charge, mea-
 .sured as the z potential, was determined in NaCl 0.85% wrv at
258C. The z potential is expressed as the mean"S.D. The
diameter of plasmid pBR322rcationic liposomes was between
0.3–3.8 mm and was between 0.1–1.0 mm for antisense
DNArcationic liposomes.
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Fig. 3. Toxicity was abolished by the incorporation of DPPE-
 .PEG 10 mol% into DOPErDOTAP cationic liposomes.2000
 5 .Macrophages or U937 monocyte-like cells 1=10 rwell were
 .incubated with DOPErDOTAP v, ’ or with DOPErDOTAP
 .  .q10 mol% DPPE-PEG ‘,^ diameter -0.11 mm for 242000
h at 378C, 5% CO , in RPMI-1640r10% FCS. Toxicity was2
determined by the release of LDH activity into the supernatant
after 24 h incubation. Data represent the mean"S.D. of two
replicates of three independent experiments.
lipids may therefore be responsible for the toxicity
observed toward macrophages. To test this hypothesis
we have replaced DOPE with DPPC. DPPC is a
pH-insensitive phospholipid that does not destabilize
the endosomal membrane. The replacement of DOPE
by DPPC in liposomes containing cationic DOTAP
did not change the z potential DOPErDOTAP:
.42.0"10.9 mV, DPPCrDOTAP: 42.6"6.8 mV .
However, as shown in Fig. 4, the progressive replace-
ment of DOPE by DPPC significantly reduced toxic-
ity towards macrophages. The replacement of DOPE
by DPPC did not completely abolished the toxicity
 .as was observed for the addition of DPPE-PEG ,2000
but the toxicity never exceed 15% at the concentra-
tions used.
3.6. DOPErDOTAP and DPPCrDOTAP are taken
up at similar rates by cells
It is possible that the reduction of toxicity ob-
served following the replacement of DOPE by DPPC
was due to a decrease in endocytosis by macrophages,
rather than a reduction in endosomal membrane
destabilization. To test this hypothesis, we have mea-
sured the uptake by adherent macrophages and non-
adherent monocyte-like U937 cells of cationic lipo-
Fig. 4. Toxicity of DOTAP-based cationic liposomes was re-
duced by the replacement of DOPE with DPPC. Macrophages
 5 .1=10 rwell were incubated for 24 h at 378C, 5% CO in2
RPMI-1640r10% FCS with 5.0 mmolrml of DOPErDOTAP
liposomes in which DOPE had been replaced by DPPC. The
liposome diameter was -0.12 mm. Toxicity was determined by
the release of LDH activity into the supernatant after 24 h
incubation. Data represent the mean"S.D. of two replicates of
three independent experiments.
somes containing the fluorescent phospholipid NB-
PE. We have observed that DOPErDOTAP and
DPPCrDOTAP were taken up at similar rates by
both macrophages and monocyte-like U937 cells Ta-
.ble 3 . However, liposomes were endocytosed by
U937 cells as approximately a 2-fold lower rate than
Table 3
Cationic liposome uptake by macrophages and monocyte-like
U937 cells
Liposome formulations Liposome endocytosis rate
5 .nmolr5=10 cellsr4 h
Macrophages Monocyte-like
U937 cells
DPPCrDOTAP 27.1"3.5 13.5"6.7
DOPErDOTAP 28.1"6.0 11.2"1.5
DOPErDDAB 34.5"8.0 9.8"4.5
DOPErDMTAP 28.8"4.4 13.4"0.9
DOPErDPTAP 27.3"5.1 21.0"2.4
DOPErDSTAP 28.8"5.6 2.2"1.2
DOPErDOTAPqDPPE-PEG 1.2"0.6 0.8"0.62000
) .DOPErDOTAP wro FCS 45.9"5.4 n.d.
 .Fluorescent cationic liposomes 10 mmolrml; -0.12 mm con-
taining 5 mgrmmol of NBD-PE were incubated for 4 h with
 5macrophages or with U937 monocyte-like cells 5.0=10
.cellsrml at 48C and at 378C, 5% CO in RPMI-1640r10%2
).FCS, or in RPMI-1640 without FCS . Endocytosis was calcu-
lated from the results obtained at 378C minus those at 48C. Data
represent the mean"S.D. of duplicate determinations of two
independent experiments.
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 .the macrophages Table 3 . All the cationic lipo-
somes tested had comparable macrophages uptake
 5 .rates 27.1–34.5 nmolr5=10 r4 h. , while the up-
take of cationic liposomes by monocyte-like U937
cells was more variable 2.2–21.0 nmole nmolr5=
5 .10 r4 h. . The absence of FCS during the incubation
of cationic liposomes with macrophages increased by
1.7-fold the amount of internalized cationic lipo-
 .somes Table 3 . Furthermore, we have found that the
addition of DPPE-PEG to DOPErDOTAP lipo-2000
somes decreases the binding and the endocytosis of
these liposomes by macrophages and by U937 mono-
 .cyte-like cells Table 3 . The inhibition of binding
and uptake by DPPE-PEG was correlated with the2000
abolition of the toxicity shown in Fig. 3.
3.7. Cationic lipids are toxic toward macrophages
Our results show that the association of DOPE and
cationic lipids is highly toxic toward macrophages
but not the association of DPPC and cationic lipid.
To evaluate if the association of DOPE and cationic
lipids is strictly necessary for the induction of toxic-
ity, we have used DOPE alone or cationic lipid alone
in our assays. DOPE or cationic lipids alone do not
form liposomes but form aggregates having diameters
)10 mm. Cationic lipids were nevertheless toxic
toward macrophages at concentrations equivalent to
those used in the liposomes, while DOPE alone was
 .not toxic Fig. 5 . The addition of DOPE synergisti-
cally enhanced the toxicity of DDAB, DOTAP and
 .DMTAP Fig. 5 .
3.8. Cationic liposomes and cationic lipids downreg-
ulate NO and TNF-a synthesis
The incubation of macrophages with 0.1 mmolrml
cationic liposomes for 3 h in the presence of FCS
was not sufficient to induce significant toxicity, but
was sufficient for the modulation of NO and TNF-a
production by LPSrIFN-g activated macrophages
 .Fig. 6a, b, c . The synthesis of NO was strongly
 .reduced in vitro by DOPErDOTAP 88% while
TNF-a synthesis was reduced by 62%. After i.p.
 .administration of DOPErDOTAP 5 mmol , in vitro
NO synthesis was inhibited by 74% and TNF-a
synthesis by 81% in LPSrIFN-g activated
macrophages. Similar results were obtained with
Fig. 5. Cationic lipids were toxic toward macrophages.
 5 .Macrophages 1=10 rwell were incubated with the indicated
 .cationic liposomes 0.10 mmolrml; diameter -0.12 mm ,
cationic lipids or DOPE concentration equivalent for the cationic
.lipids or DOPE: 0.05 mmolrml; diameters )10 mm for 24 h at
378C, 5% CO in RPMI-1640r10% FCS. Toxicity was deter-2
mined by the release of LDH activity in the supernatant. Data
represent the mean"S.D. of two replicates of three independent
experiments.
DOPErDMTAP and DOPErDDAB at different con-
 .centration data not shown . The addition of DPPE-
PEG to DOPErDOTAP or to DOPErDMTAP2000
liposomes, or the replacement of DOPE by DPPC
restored NO and TNF-a production by activated
 .macrophages to normal levels Fig. 6a, b . The down-
regulation of NO and TNF-a by activated
macrophages was not influenced by the size of the
 . liposome -0.12 mm vs. )1.00 mm data not
.shown . The incorporation of DNA, either as anti-
sense oligonucleotide or as the plasmid pBR322, in
DOPErDOTAP liposomes did not reduce their abil-
ity to downregulate NO and TNF-a synthesis by
activated macrophages. As illustrated in Fig. 6c, the
in vitro synthesis of NO and TNF-a was not restored
by the incorporation of 0.5 mg of plasmid pBR322 or
10.0 mg of antisense oligonucleotides to 0.1
mmolrml of DOPErDOTAP liposomes. Similar re-
sults were obtained with different combination of
DNArcationic liposome in vitro and in situ data not
.shown . As shown in Fig. 6d, this downregulation is
not only due to the association of DOPE with cationic
lipids but could be obtained with cationic lipids
alone. The downregulation of NO and TNF-a syn-
thesis was not permanent. The inhibition of NO and
TNF-a was reversed if macrophages initially incu-
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Fig. 6. DNA does not influence the ability of cationic liposomes and cationic lipids to downregulate in vitro and in situ NO and TNF-a
 5 . w  .  .xsynthesis. Macrophages 1=10 rwell were incubated with the indicated cationic liposomes free a, b or complexed to DNA c or
 .cationic lipids d for 3 h at 378C, 5% CO in RPMI-1640r10% FCS. The macrophages were then extensively washed and incubated2
 .  .with LPSrIFN-g b 1.0 mgrml and 500 Urml respectively for 48 h. NO was measured after 48 h in the supernatant by reaction with
 .  .  .  .  .Griess reagent a, c, d and TNF-a by commercial ELISA b, c, d . For in situ treatment in a and b , cationic liposomes 60 mgrkg
were injected i.p. in a volume of 500 ml on day 3 following the injection of thioglycollate broth. The macrophages were harvested on day
4 and NO and TNF-a synthesis measured after LPSrIFN-g stimulation as described above. Cationic liposomerDNA preparations were
 .  .  .obtained by incubating plasmid pBR322 0.5 mg or antisense DNA 10.0 mg with DOPErDOTAP 0.1 mmolrml for 30 min at room
temperature. The diameter of plasmid pBR322rcationic liposomes was between 0.8–1.6 mm and was between 0.3–0.9 mm for antisense
DNArcationic liposomes. Results are expressed as % of NO or TNF-a reduction vs LPSrIFN-g activated macrophages without
liposomes. No toxicity was observed. Data represent the mean"S.D. of two replicates of three independent experiments.
bated for 3 h with cationic liposomes were activated
by LPSrIFN-g after a minimum further 72 h of cell
 .culture without liposomes data not shown .
4. Discussion
The influence of liposome lipidrphospholipid
composition has so far been assumed to be relatively
unimportant because of the presumed inert nature of
w xlipids 17–19 and their lack of toxicity toward non-
w xphagocytic cells 6–8 . In this study we have shown
that all of the cationic liposomes tested were toxic
towards phagocytic macrophages and monocyte-like
U937 cells but were not toxic for non-phagocytic T
lymphocytes. The rank order of toxicity was
DOPErDDAB)DOPErDOTAP)DOPErDMTAP
)DOPErDPTAP)DOPErDSTAP. The ED ’s for50
macrophage toxicity were - 10 nmolrml for
DOPErDDAB, 12 nmolrml for DOPErDOTAP, 50
nmolrml for DOPErDMTAP, 400 nmolrml for
DOPErDPTAP and ) 1000 nmolrml for
DOPErDSTAP. The addition of DNA, either as
antisense oligonucleotide or as plasmid vector, did
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not reduce this toxicity. Furthermore, we have shown
that these liposomes, irrespective of whether or not
they are complexed with DNA, are capable of down-
regulating both in vitro and in situ the synthesis of
NO and TNF-a by activated macrophages.
The difference observed between macrophage and
T lymphocyte toxicity may be explained by the rela-
tive phagocytic activity of macrophages in compari-
son with T cells. Macrophages have an innate capac-
ity to non-specifically phagocytosis large quantities
of particles such as liposomes while T cells do not
w xhave this characteristic 20 . It has been shown that
macrophages can internalize liposomes containing
protein antigens, for example liposomes formulated
with DOPE and palmitoyl homocysteine or dioleoyl-
phosphatidylcholine and dioleoylphoshatidylserine,
and present their contents to T lymphocytes to initiate
w xan immune response 10,21 . The addition of DPPE-
PEG to cationic liposomes, which blocks the en-2000
docytosis of liposomes by macrophages and mono-
 .cyte-like U937 cells Table 3 , abolished their toxic-
ity. These results strongly indicate that the high
phagocytic activity of macrophages is responsible for
the high degree of toxicity. Phagocytic activity, which
is less pronounced in monocyte-like U937 cells than
 .in macrophages, as demonstrated by us Table 3 and
w xby others 22 , correlated with the lower level of
toxicity observed toward monocyte-like U937 cells in
comparison to peritoneal macrophages.
The presence of pH-sensitive DOPE in the cationic
liposomes appears to be implicated in the toxicity of
cationic lipids toward macrophages. We have found
that while all of the cationic lipids tested were toxic
in the absence of DOPE, the addition of DOPE
clearly enhanced this toxicity in a synergistic manner.
The replacement of DOPE by DPPC reduced this
toxicity. DOPE may enhance cationic lipid toxicity
by destabilizing the endosome membrane due to the
formation of an inverted hexagonal phase at acidic
.pH and thus releasing cationic lipids into the cyto-
plasm. DPPC does not possess this characteristic
w x23,24 . Non-cationic liposomes are also toxic to-
wards phagocytic cells but to a lesser extent than
cationic liposomes. We have shown previously that
liposomes composed of dipalmitoylphosphatidyl-
 .choline DPPC rdipalmitoylphosphatidylethanol-
 .amine DPPE , DPPCrdimyristoylphosphatidyl-
 .  .glycerol DMPG and DPPCrphosphatidylserine PS
phospholipids final concentration 0.5 mmol phos-
.pholipidsrml were toxic towards macrophages, al-
though the maximum toxicity never exceeded 15%
w xfor any liposome preparations 25 . In the present
study we have also shown that the toxicity of
DPPCrDOTAP liposomes is comparable to the toxi-
city observed with anionic or neutral liposomes -
.15% .
Positively charged molecules have been implicated
w xin cellular toxicity in other models 26 . Our results
show that liposome charge, as measured by the z
potential, is not an important factor in explaining this
toxicity. Although DOPErDDAB, DOPErDOTAP,
DOPErDMTAP and DPPCrDOTAP liposomes have
comparable positive z potentials, they differ signifi-
cantly in their toxicity. The incorporation of DNA in
cationic liposomes, which gave rise to a negative z
 .potential in several formulations see Table 2 , did
not abolished the toxicity observed toward
macrophages. Furthermore, the z potential of cationic
liposomes incubated overnight with RPMI-1640 con-
taining 10% FCS is slightly negative e.g.,
.DOPErDOTAP: y8.0 mV but these liposomes are
still highly toxic towards macrophages. The differ-
ences in toxicity observed in the absence and pres-
ence of FCS may be explained by the fact that FCS
interferes with cationic liposomes binding and endo-
 .cytosis this study . Litzinger et al. have reported
similar results for antisense oligonucleotide delivery
w xusing DOPErDC–Chol cationic liposomes 27 . The
observation that DOPErDPTAP and DOPErDSTAP
have toxicity comparable to DOPErDDAB,
DOPErDOTAP and DOPErDMTAP in the absence
of FCS, strongly suggests that DOPErDPTAP and
DOPErDSTAP interact differently with serum pro-
teins in a qualitative andror quantitative manner.
Membrane fluidity could explained their different
toxicity in presence of FCS. It is highly likely that
D O P E r D P T A P , D P P C r D O T A P a n d
DOPErDSTAP liposomes do not possess a fluid
membrane at 378C. DPPC, DPTAP and DSTAP have
 .liquid-crystalline transition temperatures T ofg
q41.48C, q44.58C and q55.48C respectively, while
DOTAP and DMTAP have T ’s of y16.58C andg
q34.58C respectively Pham and Phillips, unpub-
.lished observations . It is clear that DDAB, which
has a T of q46.08C, does not follow this pattern,g
but its chemical structure is different from the ‘tri-
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methylammonium propane’ series. We are currently
evaluating the T of cationic liposomes in the absenceg
and presence of DNA.
It is clear that under non-toxic condition, cationic
liposomes are not inert. Cationic liposomes, via their
cationic lipid component, can downregulate at least
two immunomodulators, NO and TNF-a , produced
by activated macrophages. The downregulation of
NO and TNF-a synthesis by cationic liposomes may
be explained by the fact that cationic lipids modulate
 .the activity of protein kinase C PKC activity. Bot-
w xtega and Epand 28 have shown that positively
charged amphiphiles inhibit PKC activity, while Far-
w xhood et al. 29 have obtained similar results with
cationic derivatives of cholesterol that are currently
used in cationic liposomes. The inhibition of PKC
activity has been shown to inhibit the transfection
w xactivity of nucleic acids 29 . The biosynthesis of NO
w xand TNF-a are PKC-dependent processes 30,31 .
The downregulation of NO and TNF-a synthesis by
the cationic liposomes used in this study can be
correlated with their ability to inhibit PKC activity
 .Filion and Phillips, manuscript submitted . The use
of cationic liposomes to deliver antisense oligo-
nucleotides to macrophages or other phagocytic cells
may therefore not be appropriate. Non-specific modu-
lation by cationic lipids of the level of expression of
several molecules that depend directly or indirectly
on PKC activity, as illustrated here by the downregu-
lation of NO and TNF-a synthesis, may lead to a
misinterpretation of the data obtained. Furthermore,
NO and TNF-a have significant roles in immune and
w xinflammatory processes 11,12 . In fact, we have
shown that cationic liposomes, irrespective of whether
or not they are complexed to DNA, have potent
anti-inflammatory activity in vivo Filion and Phillips,
.manuscript submitted .
Cationic liposomes should perhaps be used with
caution to deliver DNA in vivo, especially in anti-
sense oligonucleotides therapy which requires the
long-term administration of large amounts of DNA
for therapeutical efficacy. For example, the adminis-
tration of 6 mgrkgrday of antisense oligonucleotide
directed against PKC-a mRNA for at least 24 days is
necessary to completely inhibit the growth of tumors
w xin mice 32 . In humans, clinical studies with 0.1
mgrkg of antisense oligonucleotides complementary
w xto gag gene of HIV-1 has been carried-out 33 . In
such cases, the adoption of a cationic liposome deliv-
ery strategy to increase the stability of the antisense
oligonucleotides represents the administration of ap-
proximately 1–60 mgrkgrday of cationic liposomes
using a cationic liposomerDNA ratio of 10:1. In this
study we have shown than in vivo treatment with
3.75, 15.0 or 60.0 mgrkg of cationic liposomes
significantly decreases the synthesis of NO and TNF-
a by activated macrophages is associated with anti-
inflammatory activity Fig. 6 and Filion and Phillips,
.manuscript submitted . Furthermore it has been shown
that the association of oligonucleotides and cationic
liposomes formulated with DC–Chol forms aggre-
gates that are capable of accumulating within pul-
monary capillaries and provoking the formation of
w xemboli 27 .
The use of cationic liposomes to deliver gene
therapy via plasmid vector is less problematic. Stable
gene transfer can be achieved with a single dose of
DNA-liposome complex. For example, gene expres-
sion following the i.v. administration of chloramphe-
nicol acetyltransferase reporter plasmid complexed
with liposomes formulated from DOPE and dioctade-
cemyloxypropyltrimethylammonium chloride
 . w xDOTMA was detected for up to 9 weeks 34 .
However, we feel it prudent to highlight the fact that
cationic liposomes have been reported to have several
adverse effects other than the downregulation of NO
and TNF-a synthesis. Liposomal vectors formulated
 .with positively-charged stearylamine SA , DOTMA
or dihexadecyloxylpropyltrimethylammonium chlo-
 .ride BisHOP have been shown to interact with
serum proteins and red blood cells, inducing a strong
w xclotting response and haemolysis respectively 26,35 .
The presence of a positive charge at the surface of
liposomes formulated with SA or BisHOP is also
associated with an enhancement of their blood clear-
w xance rates 36 . Liposomes based on SA or DOTAP
cationic lipids can also activate complement via the
w xalternative pathway 37 . These complement-activat-
ing liposomes have C3b associated with their mem-
brane which enhances the recognition of liposomes
by the immune system as foreign particles. Further-
more, it has been shown that cationic DOPErDOTAP
liposomes can induce epithelial necrosis at terminal
and respiratory bronchi, alveolar ducts and alveoli
w xfollowing pulmonary administration 38 .
It is clear from the present study that cationic
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liposomes should be used with caution for the intra-
cellular delivery of DNA to macrophages. Cationic
liposomes, whether or not they are complexed with
DNA, are highly toxic in vitro toward macrophages,
but not toward non-phagocytic T cells. The downreg-
ulation by cationic liposomes under non-toxic condi-
 .tions of at least two of the immunomodulators
produced by activated macrophages should also be
take in consideration. The impact of cationic lipid-in-
duced macrophage downregulation on gene expres-
sion or on macrophage-related host defence is at
present unknown.
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